Interview: iTeos Attracts Investors By Targeting TIGIT
Series B2 Financing Raises $125m
The Belgian biotech has managed to attract considerable sums from venture capitalists over the past couple of years amid hopes that its two next-generation immunotherapies will be best-in-class agents.
